C ounterfeit drugs are not a new problem worldwide. Over the years, there have been several reports about the proliferation of fake or substandard pharmaceuticals in India, Africa, Brazil, Cambodia, and many other countries. [1] [2] [3] [4] [5] [6] In the US, however, drug counterfeiting has been a limited problem -that is, until recently.
During the past few years, several batches of counterfeit medications have been discovered here. The most notable of these were counterfeit Procrit, Serostim, and Combivir. Late this spring, pharmacists and other health care professionals learned about the recall of another counterfeit medication, namely fake Lipitor.
In late spring 2003, the FDA announced that Albers Medical Distributors, Inc, were voluntarily recalling specific lots of Lipitor believed to be counterfeit. [7] [8] [9] The counterfeit product was very similar in appearance to the authentic brand. In fact, only minor differences in package labeling differentiated the phony product from the real thing.
All patients and health professionals were encouraged to check the Lipitor product package carefully for labeling that stated "Repackaged by MED-PRO, Inc.; Lexington, NE 68550." If the counterfeit product was found, patients were instructed to return it to the pharmacy. The FDA noted that the safety and efficacy of counterfeit products could not be ensured and that these products represented a health risk to patients.
The extent of fake medications in the US is not known, but the FDA has investigated 71 cases of counterfeit drugs since 1996. The distribution of counterfeit medications represents a new type of epidemic for health professionals, requiring increased vigilance in postmarketing surveillance. This issue is multifaceted in its consequences and possible solutions. Issues surrounding drug counterfeiting include patient safety risks, the need to create more secure packaging and drug distribution channels, increased awareness by health professionals about lack of therapeutic benefit, reporting of events to the FDA, and improved dissemination of information about such events. This problem will require collaborative efforts among the FDA, manufacturers, state boards of pharmacy, and national health society organizations.
As pharmacists, we are challenged in this new environment to reevaluate lack of patient response in a new light. Thus, another layer of complexity has been added to patient care. Keeping current with FDA investigations and bulletins regarding anti-counterfeiting measures is a top priority and can be easily achieved via access to the MedWatch Web site (http://www. fda.gov/medwatch/safety.htm). When a counterfeit drug is announced, all pharmacists should be involved in disseminating this information to appropriate members of the medical staff and patients, following the guidance of professional societies and state boards.
